Fran M. Gengo
PharmD
Dr. Gengo serves as Director of Neuropharmacology and the Research Director for the Acute Stroke Treatment Program at DENT, as well as the the Chief Science Officer for DENT’s research affiliate, DNRC. Dr. Gengo is also the Neuropharmacological Director for the DENT Cannabis Clinic.
Dr. Gengo is located at DENT Tower in Amherst.
He is currently involved in several protocols of thrombolytics and neuroprotective agents. In addition, he is an Associate Professor of Pharmacy and Neurology and a Clinical Assistant Professor of Neurosurgery at the SUNY at Buffalo School of Medicine.
Dr. Gengo has published numerous papers on the effects of various drugs on the central nervous system and his research entails abstraction and statistical analysis of data acquired from several modalities.
SPECIALITIES
- Neurology
- Neuropharmacology
- Pharmacotherapy
Board Certifications
- 2005 Neurology
- 2011 Neuroimaging
- 2016 Neurology
Publications
See publications for Fran M. Gengo, PharmD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with DENT Neurologic Institute)
Titles
- Director of Neuropharmacology
- Research Director, DENT Acute Stroke Treatment Program
- Chief Science Officer, DENT’s research affiliate, DNRC.
- Neuropharmacological Director, DENT Cannabis Clinic.
- Associate Professor of Pharmacy and Neurology, SUNY at Buffalo School of Medicine
- Clinical Assistant Professor of Neurosurgery, SUNY at Buffalo School of Medicine.
Education
Medical / Graduate Education
Philadelphia College of Pharmacy and Science, Philadelphia, PA
Fellowship
SUNY at Buffalo, Department of Pharmaceutics, Buffalo, NY – Pharmacokinetics and Biopharmaceutics
Open Clinical Trials
ADNI3 Trial
ADNI3 Trial Dent is taking part in an observational study called the ADNI3 Trial. This historic study of brain aging could help change the future …
Hearing Aid Research
Hearing Aid Research Are you interested in participating in hearing aid research? Dr. Zhang is collaborating with Dr. Wei Sun at UB and is recruiting …
CGBG Study
We are looking for adults ages 18 to 55 who have been diagnosed with migraine. The CGBC Study will consist of five visits over a period of up to five weeks.
PADOVA
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease
STARS and STARS Extension
Studies to Assess the Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects Inclusion Criteria Age 55-90 years Have a reliable study partner, …
MT-1186-A02
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
ENVISION
ENVISION Trial The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as …
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)
The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.
Meniere’s Study
Meniere’s Study Have you been diagnosed with Meniere’s Disease? Do you frequently experience vertigo? If you answered yes to these questions and are over the …
RECOVER VNS
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
PROSEEK
PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug …
Signal – AD
Signal- AD Trial The purpose of the study is to investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in people with …
ADNI4 Trial
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive …
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Call us to schedule an appointment
Our entire team, from customer service to patient providers, is focused on the central mission to deliver superior clinical care, advanced neurodiagnostics, clinical research and education that will assist our patients in maximizing their quality of life. We strive to exceed the expectations of our patients, clinical partnerships and community partners.